Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.53 is 61% above its 5-year average of -9.06, near the high end of its 5-year range (-31.20–-3.32).
3.29% above its 12-month average of -3.65.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.05.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-3.53
EARNINGS PER SHARE (EPS) AVG TTM
-3.65
EARNINGS PER SHARE (EPS) AVG 3Y
-4.13
EARNINGS PER SHARE (EPS) AVG 5Y
-9.06
EARNINGS PER SHARE (EPS) AVG 10Y
-13.68
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.29%
CURRENT VS 3Y AVG
+14.53%
CURRENT VS 5Y AVG
+61.05%
CURRENT VS 10Y AVG
+74.20%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Earnings Per Share (EPS)
-3.53
TTM Avg
-3.65
3Y Avg
-4.13
5Y Avg
-9.06
Market Cap
$2.06B
Earnings Per Share (EPS)
-4.36
TTM Avg
-3.17
3Y Avg
-2.92
5Y Avg
-2.56
Market Cap
$2.05B
Earnings Per Share (EPS)
0.47
TTM Avg
0.27
3Y Avg
0.03
5Y Avg
0.00
Market Cap
$2.02B
Earnings Per Share (EPS)
-1.50
TTM Avg
0.42
3Y Avg
-0.42
5Y Avg
-0.63
Market Cap
$2.11B
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.38
3Y Avg
-1.05
5Y Avg
-1.28
Market Cap
$2.02B
Earnings Per Share (EPS)
-1.98
TTM Avg
-3.08
3Y Avg
-3.62
5Y Avg
-4.23
Market Cap
$2.02B
Earnings Per Share (EPS)
2.29
TTM Avg
1.09
3Y Avg
0.22
5Y Avg
-0.23
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | -3.53 | -3.65 | -4.13 | -9.06 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -4.36 | -3.17 | -2.92 | -2.56 |
| Alvotech (ALVO)vs › | $2.08B | -0.63 | -0.39 | -1.45 | -2.42 |
| Vericel Corporation (VCEL)vs › | $2.05B | 0.47 | 0.27 | 0.03 | 0.00 |
| Progyny, Inc. (PGNY)vs › | $2.03B | 0.92 | 0.64 | 0.56 | 0.59 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | -1.50 | 0.42 | -0.42 | -0.63 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -0.21 | -0.38 | -1.05 | -1.28 |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | -1.98 | -3.08 | -3.62 | -4.23 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 2.29 | 1.09 | 0.22 | -0.23 |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | -5.86 | -3.71 | -3.25 | -4.97 |
Trailing EPS (TTM)
$-3.53
Forward EPS (Est.)
$-3.92
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.32 |
| 2024-12-31 | -3.98 |
| 2023-12-31 | -5.31 |
| 2022-12-31 | -3.91 |
| 2021-12-31 | -6.66 |
| 2020-12-31 | -31.20 |
| 2019-12-31 | -20.31 |
| 2018-12-31 | -16.57 |
| 2017-12-31 | -20.66 |
| 2016-12-31 | -17.57 |
| 2015-12-31 | -21.00 |
| 2014-12-31 | -52.46 |
| 2013-12-31 | -11.48 |
| 2012-12-31 | -38.75 |
